<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=2025632344154429&amp;ev=PageView&amp;noscript=1">

Healthcare Innovation 360o Asia 

A collaboration by SPRIM and CIH of NUHS.

We empower, support and strategically nurture healthcare innovation companies and organisations for the next level of success.

Providing clinical, business and next-stage financial support in healthcare innovation, we're backed by panels of clinical and pragmatic business experts in a first-of-its-kind hospital and private sector partnership.

Complete the form provided to get in touch.

Learn more about us below.

Engagement Form

---------------- 

 

scientific-formulation.png

Clinical Problem Statement – Formulation / Qualification

Having the right problem statement is crucial to any healthcare innovation. Having an over-engineered solution to the wrong problem statement is painful. Do speak to our clinicians early in your innovation Journey. (In addition, get a direct input From Key Opinion Leader / KOL)

clinical-iteration.png

Clinical Opinion - Innovation Iterations

Healthcare innovations typically go through a few iterations before a best in class solution is formed. Having KOL opinion on this iteration phase is important to give an innovation the greatest viability for market adoption.

intellectual-property.png

Technology Landscaping / IP Positioning (Meta Analysis)

IP strategy and positioning is an important anchor-point for your innovation and we can help by advising you on ring-fencing your innovation as well as strategising the IP value of your innovation in comparison to the technology landscape your innovation plays in.

clinical-tactics.png

Clinical Strategy (Trial Design / Protocol)

We will help to match you to a Principal Investigator whom can lend strategic value in your clinical trial strategy

test-bed.png

Test Bedding in Institution Setting NUHS / Alexandra Campus

Offering access to a full patient ward with 36 beds and a test bed site with 8 beds at Alexandra Hospital within the NUHS Cluster.

clinical-application-development.png

Digitised Test Bedding via ObvioHealth Proprietary Platform (Institution To Community)

Offers an effective and productive online way to test bed Class 1 and selective Class 2 devices from Hospital to Community/Home.

path-startup.png

Path To Market / Market Entry Plan / Regulatory Advisory, Market Access And Path To Claims

Through our panel of clinical, industry and capital partners, we help you shape the clearest path to market. The team takes an extremely pragmatic view on path to market and hopes to support you in each step to the market.

economic-graph.png

Cost Benefit Analysis / Economic Modelling

In addition to clinical value proposition, sharpening your innovation with an economic value proposition adds strong value to your proposed healthcare solution.

funding-signature.png

Capital Needs - Investor Presentations and Fund Raising

We recognize the need for strategic capital to be there when you need it. With access to TKS1, a healthcare and life science focused venture fund, in partnership with Tikehau Capital, we are happy to facilitate pitching sessions to strategic capital partners.

About Obvio Health
 

About CIH

 

 

---------------- 

 

NUHS logo (400dpi).png

National University Health System (NUHS)

The National University Health System (NUHS) is an integrated Academic Health System and Regional Health System in Singapore that delivers value-driven, innovative and sustainable healthcare.

Learn More here.

Something Powerful

Tell The Reader More

The headline and subheader tells us what you're offering, and the form header closes the deal. Over here you can explain why your offer is so great it's worth filling out a form for.

Remember:

  • Bullets are great
  • For spelling out benefits and
  • Turning visitors into leads.
SPRIM_Ventures_logo.jpg

SPRIM Ventures

SPRIM VENTURES invest in early stage health solutions leveraging the funnel of SPRIM’s sourcing, screening and selection processes.

SPRIM VENTURES benefits from SPRIM’s unique combination of skills and resources:

Strong and long established relationships with large healthcare companies. Global infrastructure of 19 offices around the world. Potential partnerships with more than 400 global customers.

Learn More here.

TKS1 Venture Capital Fund

Tikehau Capital and SPRIM Ventures have raised $50 million in its initial closing for their first venture capital fund TKS1, which will focus on early stage investments in med-tech and life science companies.

Learn More here.

---------------- 

 


Are you a market-ready pre-Series A, early stage startup with valuation around 100-200K USD?

Are you based in or interested in entering Asia Pacific?

Are you comfortable with pitching in English?

Do you have a fantastic innovation prototype / product in healthcare?

Are you seeking Funds or Business opportunities with the region’s most active investors and medtech corporates?

 

---------------- 

 

initiation-innovation-investment-cycle

---------------- 

 

Prof-Lawrence-Ho.png

Prof Lawrence Ho

Centre Lead,
CIH

Freddy-Boey-HiRes.jpg

Prof Freddy Boey

SVP, Grad Ed &
Res Trans. NUS

Prof-Lim-Chwee-Teck-HiRes.jpg

Prof Lim Chwee Teck

Acting Director,
BIGHEART, NUS

Richard-HiRes.jpg

Mr Richard Lim

NUHS Board
Member

Chang-Yew-Kong-HiRes.jpg

Mr Chang Yew Kong

Smart Patient,
System Advisor

Ngiam-Kee-Yuan-Hires.jpg

A/Prof Ngiam Kee Yuan

CTO, NUHS,
Dir. Surgical R&D

Michael-HiRes.png

Dr. Michael Shleifer, PhD

Managing Partner
SPRIM

laurent-HiRes.jpg

Laurent Benissan

Co-Founder
SPRIM

 

 

---------------- 

 

Prof-Lawrence-Ho.png

Prof Lawrence
Ho

Centre Lead,
CIH

Rasiah-HiRes.jpeg

Prof Ignatius
Rasiah

Prog. Dir. Institute of
Engr. Leaders.

Michael-HiRes.png

Dr. Michael
Shleifer, PhD

Managing Partner
SPRIM

laurent-HiRes.jpg

Laurent
Benissan

Co-Founder
SPRIM

Bruno-Tikehau.png

Bruno de
Pampelonne

Chairman
TIKEHAU

 

 

---------------- 

 

Endomasterlogo___234x131.jpg

Endomaster Pte Ltd

Endomaster produces a robotic-assisted surgical system for the removal of gastro-intestinal cancer through an endoscopic approach. 

endofotonic logo.png

Endofotonics Pte Ltd

Endofotonics’ IMDX™ system is built on the Raman Spectroscopy technique – a vibrational technique capable of probing biomolecular changes associated with cellular transformation.

CBA-transparent-300x151.png

Clearbridge Accelerator

Clearbridge Accelerator is an incubator that focuses on Healthcare innovation such as precision medicine technology for disease treatment and prevention.

 

clearbridge biomedics.png

Clearbridge BioMedics Pte Ltd

Clearbridge BioMedics (CBB) specialises in novel platforms with applications in oncology research and diagnostics.

flexosense.png

Flexosense Pte Ltd

FlexoSense is a spin-off from the National University of Singapore incorporated in 2016. The co-founders have experiences in startups, R&D, business development, sales & marketing, operations, and finance.

amaranth medical.png

Amaranth Medical

Amaranth Medical is dedicated to advancing the field of interventional cardiology through the development of the thinnest bioresorbable drug eluting scaffolds that perform like metallic stents.

peregrine logo.png

Peregrine Ophthalmic Pte Ltd

Combining 50 years of experience in materials science and technology with our in-depth expertise of ophthalmology to develop proprietary drug delivery systems for the eye.

Robust Dynamic.png

Robust Dynamics Pte Ltd

Robust Dynamics helps designers and manufacturers improve the physical robustness of products and components, particularly in the area of withstanding impacts and shocks.

 

logo-medilot.png

MediLOT Technologies

MediLOT is a decentralised healthcare platform built on blockchain, Artificial Intelligence and database management system technologies for patients, healthcare providers, researchers and commercial companies.

 

Medical advancements are extending life spans. Big data will uncover a cure for cancer, nanotechnology will change drug delivery and targeted therapy, and three-dimensional (3D) printing will make prosthetics affordable and liberating. It is not hard to conceive that life expectancy may almost double to 150 years of age.

- Mark Barrenechea, OpenText CEO -